Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

据卢特尼克表示，总统特朗普正在调动多个行政部门机构以实现这一目标。"我刚刚接到(卫生部长)博 比·肯尼迪的电话。我还接到了(美国医疗保险和医疗补助服务中心主任)梅赫迈特·奥兹的电话，他们都 和我说，'好吧，让我们开始推进这件事吧'。"卢特尼克在采访中补充说。 总部位于美国的吉利德(GILD.US)、百时美施贵宝(BMY.US)、强生(JNJ.US)、再生元(REGN.US)、安进 (AMGN.US)以及艾伯维(ABBV.US)，还包括总部位于欧洲的大型药企默克集团(Merck KGaA)、赛诺菲 (SNY.US)、葛兰素史克(GSK.US)、阿斯利康(AZN.US)、诺和诺德(NVO.US)、罗氏(RHHBY.US)以及诺 华(NVS.US)也收到了特朗普的来信。 "总统将会说，大型药品制造商们如果不在那边以更高的价格进行出售，就不能在这里销售。别再愿意 以那么低的价格卖给他们了。"卢特尼克在采访中表示。特朗普给药企们设定遵守该最惠国政策的最后 期限为9月29日，并且他在此之前作出了上述的坚定表态。 智通财经APP获悉，美国商务部长霍华德·卢特尼克近日在接受媒体采访时表示，总统唐纳德·特朗普正 在联合多个联邦 ...

Key Takeaways Sanofi gained FDA fast track designation for its gene therapy SAR402663 in wet AMD.The tag allows rolling review, expediting SAR402663's regulatory process.SAR402663 targets VEGF to reduce abnormal eye vessel growth and treatment burden.Sanofi (SNY) announced that the FDA granted fast track designation to its investigational gene therapy, SAR402663, for the treatment of neovascular (or wet) age-related macular degeneration (AMD).How Does the Fast Track Tag Benefit SNY’s Drug Development?Fast t ...

Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degenerationNeovascular or “wet” age-related macular degeneration can lead to significant vision loss and affects more than one million people in the US Paris, September 11, 2025. The US Food and Drug Administration (FDA) has granted fast tr ...

Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degenerationNeovascular or “wet” age-related macular degeneration can lead to significant vision loss and affects more than one million people in the US Paris, September 11, 2025. The US Food and Drug Administration (FDA) has granted fast tr ...

赫希斯特工业园概况 - 园区占地460公顷 是欧洲最大化工与制药研发生产基地之一 汇聚90余家全球顶尖化工制药企业[2] - 拥有150年发展历史 集中展示德国化工制药产业全球领先优势[2] - 采用一体化布局 配备独立发电厂 加氢站和港口设施 提供能源原料供应 废弃物处理 物流运输 职业培训等全方位配套服务[1] 园区企业与合作动态 - 赛诺菲2024年投资13亿欧元扩建全球最大胰岛素生产基地[2] - 初创企业正在建设新型锂电解工厂和塑料降解实验室[2] - 成为赛诺菲 科莱恩 拜耳 默克 朗盛等跨国公司重要生产研发基地[1] 中德合作机遇 - 园区可成为中国企业融入欧洲产业生态桥头堡 对华合作前景广阔[2] - 中资企业与园区在研发中心 新能源 生物医药 数字技术等新兴领域开展务实合作[2] - 中石化 上海电力 华为等20余家企业代表表达加强后续合作积极意愿[1][2] 产业吸引力 - 区位优势显著 欢迎中国高端化工制药企业及研发机构落户[1] - 黑森州化工协会主席亲自推介园区历史 运营模式与企业发展规划[1]

Accessibility StatementSkip Navigation MORRISTOWN, N.J., Sept. 10, 2025 /PRNewswire/ -- Sanofi is partnering with celebrity moms who chose to immunize their babies with BEYFORTUSÂ (nirsevimab-alip) to help educate families about the importance of RSV infant protection. BEYFORTUS is the first long-acting monoclonal antibody approved to prevent a serious RSV lung infection in newborns and infants entering their first RSV season, as well as in children up to 24 months of age who remain at risk for severe RSV t ...

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes         Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older, with stage 2 T1D compared to placeboAdditional regulatory reviews are ongoing across different disease stages by regulatory authorities around the world Paris, September 10, 2025- The Chinese National Medical Products Admi ...

Question-and-Answer SessionI thought perhaps we could start with an update on U.S. policy, albeit I'm sure you're sick of talking about it. But on tariffs, we're still awaiting the specifics, but how should we think about Sanofi's potential exposure to U.S. tariffs? Could you give us an indication of the percentage of U.S. sales driven by U.S. manufacturing?Paul HudsonCEO & Director So very happy to be here. Great first question. For tariffs, I think most of us have a placehold of around 15% for 2025. I thi ...

    September 9, 2025 – TheNewswire - Rouyn Noranda, Quebec, Granada Gold Mine Inc. (TSXV: GGM) (the “Company” or “Granada”) is pleased to announce that Heidi Gutte has been appointed as Chief Financial Officer of the Company effective today, replacing the Company’s CFO, Remantra Sheopaul. Heidi Gutte has nearly 15 years of experience with publicly-traded mineral exploration and mining companies. She specializes in corporate finance, IFRS financial reporting, audit preparation and response, tax optimizatio ...